Lupin receives US FDA approval for Sertraline

BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN

Mumbai, February 7 2007: Lupin Ltd. today announced that the US FDA has approved the Company's Abbreviated New Drug Application (ANDA) for Sertraline Hydrochloride Tablets, 25mg, 50mg and 100mg. Sertraline Hydrochloride is indicated for the treatment of major depressive disorder.

Lupin's Sertraline Tablets are the AB-rated generic equivalent of Pfizer's Zoloft® Tablets. The brand product had annual sales of approximately US$2.1 billion for the 12-month period ended December 2006, according to IMS Health.

With this approval, Lupin now has 18 ANDAs approved by the US FDA.

About Lupin

Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with a strong research focus. It has a programme for developing New Chemical Entities. The Company has a state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDs and Asthma.

For the nine-month period ended December 2006, the Company's Revenues and Profit after Tax were Rs.14,985 million (US$ 335 million) and Rs.1,650 million (US$ 37 million) respectively**.**

For further information contact:
Raju Kane
The Source
Tel. +91 22 24901327/28
Telefax: +91 22 24901325
Mobile: +91 98200 45656
E-mail: rajukane@sourcepr.com